Effects of statins on α7 nicotinic receptor, cholinesterase and α-form of secreted amyloid precursor peptide in SH-SY5Y cells

Neurochemistry International

Volumn 50, Issue 6, 2007, Pages 800-806

  Roensch, Julia ^a   Crisby, Milita ^a   Nordberg, Agneta ^a   Xiao, Yan ^b   Zhang, Lan Jiang ^b   Guan, Zhi Zhong ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b GUIZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Form of secreted amyloid precursor peptide; Cholinesterase; Neuroblastoma cells; Nicotinic receptor; Statins

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID PRECURSOR PROTEIN; ATORVASTATIN; BUNGAROTOXIN RECEPTOR; CHOLINESTERASE; MEVINOLIN; ROSUVASTATIN; SIMVASTATIN; STATIN; ALPHA-BUNGAROTOXIN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; NEUROPROTECTIVE AGENT; NICOTINIC RECEPTOR; SECRETASE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CANCER CELL CULTURE; COLORIMETRY; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROPHILICITY; LIPOPHILICITY; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BIOSYNTHESIS; CELL LINE; CELL SURVIVAL; DRUG EFFECT; GENETICS; METABOLISM;

ACETYLCHOLINESTERASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; BLOTTING, WESTERN; BUTYRYLCHOLINESTERASE; CELL LINE; CELL SURVIVAL; CHOLINESTERASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEUROPROTECTIVE AGENTS; RECEPTORS, NICOTINIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TETRAZOLIUM SALTS; THIAZOLES;

EID: 34248208657     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2007.02.001     Document Type: Article

References (59)

1. Alvarez A., Opazo C., Alarcon R., Garrido J., and Inestrosa N.C. Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. J. Mol. Biol. 272 (1997) 348-361
2. Alvarez A., Alarcon R., Opazo C., Campos E.O., Munoz F.J., Calderon F.H., Dajas F., Gentry M.K., Doctor B.P., De Mello F.G., and Inestrosa N.C. Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J. Neurosci. 18 (1998) 3213-3223
3. Araki W., Kitaguchi N., Tokushima Y., Ishii K., Aratake H., Shimohama S., Nakamura S., and Kimura J. Trophic effect of beta-amyloid precursor protein on cerebral cortical neurons in culture. Biochem. Biophys. Res. Commun. 181 (1991) 265-271
4. Arendt T., Bruckner M.K., Lange M., and Bigl V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development-a study of molecular forms. Neurochem. Int. 21 (1992) 381-396
5. Baskin F., Rosenberg R.N., Fang X., Hynan L.S., Moore C.B., Weiner M., and Vega G.L. Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients. Neurology 60 (2003) 2006-2007
6. Björkhem I., and Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler. Thromb. Vasc. Biol. 5 (2004) 5
7. Coyle J.T., Price D.L., and DeLong M.R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219 (1983) 1184-1190
8. Crisby M. The role of pleiotropic effects of statins in dementia. Acta. Neurol. Scand. 185 (2006) 115-118
9. Danesh F.R., Sadeghi M.M., Amro N., Philips C., Zeng L., Lin S., Sahai A., and Kanwar Y.S. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: implications for diabetic nephropathy. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 8301-8305
10. Darreh-Shori T., Almkvist O., Guan Z.Z., Garlind A., Strandberg B., Svensson A.L., Soreq H., Hellstrom-Lindahl E., and Nordberg A. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 59 (2002) 563-572
11. Darvesh S., Martin E., Walsh R., and Rockwood K. Differential effects of lipid-lowering agents on human cholinesterases. Clinic. Biochem. 37 (2004) 42-49
12. Desdouits-Magnen J., Desdouits F., Takeda S., Syu L.J., Saltiel A.R., Buxbaum J.D., Czernik A.J., Nairn A.C., and Greengard P. Regulation of secretion of Alzheimer amyloid precursor protein by the mitogen-activated protein kinase cascade. J. Neurochem. 70 (1998) 524-530
13. Dickson D.W. Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies. Neurobiol. Aging 18 (1997) S21-S26
14. Ellman G.L., Courtney K.D., Andres Jr. V., and Feather-Stone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7 (1961) 88-95
15. Famer D., and Crisby M. Rosuvastatin reduces caspase-3 activity and up-regulates alpha-secretase in human neuroblastoma SH-SY5Y cells exposed to A beta. Neurosci. Lett. 371 (2004) 209-214
16. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P., Runz H., Kuhl S., Bertsch T., von Bergmann K., Hennerici M., Beyreuther K., and Hartmann T. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 5856-5861
17. Gillespie S.L., Golde T.E., and Younkin S.G. Secretory processing of the Alzheimer amyloid beta/A4 protein precursor is increased by protein phosphorylation. Biochem. Biophys. Res. Commun. 187 (1992) 1285-1290
18. Grutzendler J., and Morris J.C. Cholinesterase inhibitors for Alzheimer's disease. Drugs 61 (2001) 41-52
19. Haass C., and Selkoe D.J. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell 75 (1993) 1039-1042
20. Hellström-Lindahl E., Court J., Keverne J., Svedberg M., Lee M., Marutle A., Thomas A., Perry E., Bednar I., and Nordberg A. Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice. Eur. J. Neurosci. 19 (2004) 2703-2710
21. Hu W., Gray N.W., and Brimijoin S. Amyloid-beta increases acetylcholinesterase expression in neuroblastoma cells by reducing enzyme degradation. J. Neurochem. 86 (2003) 470-478
22. Huang S.M., Mouri A., Kokubo H., Nakajima R., Suemoto T., Higuchi M., Staufenbiel M., Noda Y., Yamaguchi H., Nabeshima T., Saido T.C., and Iwata N. Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J. Biol. Chem. 281 (2006) 17941-17951
23. Inestrosa N.C., Sagal J.P., and Colombres M. Acetylcholinesterase interaction with Alzheimer amyloid beta. Sub. Cell. Biochem. 38 (2005) 299-317
24. Jick H., Zornberg G.L., Jick S.S., Seshadri S., and Drachman D.A. Statins and the risk of dementia. Lancet 356 (2000) 1627-1631
25. Kojro E., Gimpl G., Lammich S., Marz W., and Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 5815-5820
26. Liu Y., Peterson D.A., Kimura H., and Schubert D. Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J. Neurochem. 69 (1997) 581-593
27. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 430 (2004) 631-639
28. Mesulam M., Guillozet A., Shaw P., and Quinn B. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol. Dis. 9 (2002) 88-93
29. Mesulam M.M., Brimijoin S., and Geula C. Neurofibrillary tangles have no obligatory predilection for acetylcholinesterase-rich neurons. Neurobiol. Aging 15 (1994) 615-619
30. Misiti F., Clementi M.E., Tringali g., Vairano M., Orsini F., Pezzotti M., Navarra P., Giardina B., and Pozzoli G. Fragment 31-35 of beta-amyloid peptide induces neurodegeneration in rat cerebellar granule cells via vax gene expression and caspase-3 activation. A crucial role for the redox state of methionine-35 residue. Neurochem. Int. 49 (2006) 525-532
31. Muacevic-Kataneca D., Bradamante V., Reinec Z., Sucic M., Poljicanin T., Busljeta I., and Metelko Z. Clinical study on the effect of simvastatin on butyrylcholinesterase activity. Arzneimittelforschung 55 (2005) 271-275
32. Nordberg A. Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. Biol. Psychiatry 49 (2001) 200-210
33. Nordberg A. Toward an early diagnosis and treatment of Alzheimer's disease. Int. Psychogeriatr. 15 (2003) 223-237
34. Paterson D., and Nordberg A. Neuronal nicotinic receptors in the human brain. Prog. Neurobiol. 61 (2000) 75-111
35. Pedrini S., Carter T.L., Prendergast G., Petanceska S., Ehrlich M.E., and Gandy S. Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med. 2 (2005) e18
36. Puglielli L., Tanzi R.E., and Kovacs D.M. Alzheimer's disease: the cholesterol connection. Nat. Neurosci. 6 (2003) 345-351
37. Refolo L.M., Pappolla M.A., LaFrancois J., Malester B., Schmidt S.D., Thomas-Bryant T., Tint G.S., Wang R., Mercken M., Petanceska S.S., and Duff K.E. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8 (2001) 890-899
38. Roman S., Badia A., Camps P., Munoz-Torrero D., and Clos M.V. Nicotinic-receptor potentiator drugs, huprine X and galantamine, increase ACh release by blocking AChE activity but not acting on nicotinic receptors. Brain Res. 1061 (2005) 73-79
39. Saez-Valero J., Fodero L.R., White A.R., Barrow C.J., and Small D.H. Acetylcholinesterase is increased in mouse neuronal and astrocyte cultures after treatment with beta-amyloid peptides. Brain Res. 965 (2003) 283-286
40. Selkoe D.J. Amyloid beta-protein precursor: new clues to the genesis of Alzheimer's disease. Curr. Opin. Neurobiol. 4 (1994) 708-716
41. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81 (2001) 741-766
42. Simons K., and Ehehalt R. Cholesterol, lipid rafts, and disease. J. Clin. Invest. 110 (2002) 597-603
43. Simons M., Schwarzler F., Lutjohann D., von Bergmann K., Beyreuther K., Dichgans J., Wormstall H., Hartmann T., and Schulz J.B. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol. 52 (2002) 346-350
44. Small D.H., Nurcombe V., Reed G., Clarris H., Moir R., Beyreuther K., and Masters C.L. A heparin-binding domain in the amyloid protein precursor of Alzheimer's disease is involved in the regulation of neurite outgrowth. J. Neurosci. 14 (1994) 2117-2127
45. Smith-Swintosky V.L., and Mattson M.P. Glutamate, beta-amyloid precursor proteins, and calcium mediated neurofibrillary degeneration. J. Neural. Transm. Suppl. 44 (1994) 29-45
46. Sparks D.L., Sabbagh M., Connor D., Soares H., Lopez J., Stankovic G., Johnson-Traver S., Ziolkowski C., and Browne P. Statin therapy in Alzheimer's disease. Acta Neurol. Scand. 185 (2006) 78-86
47. Sparks D.L., Sabbagh M.N., Connor D.J., Lopez J., Launer L.J., Browne P., Wasser D., Johnson-Traver S., Lochhead J., and Ziolwolski C. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch. Neurol. 62 (2005) 753-757
48. Stuve O., Youssef S., Steinman L., and Zamvil S.S. Statins as potential therapeutic agents in neuroinflammatory disorders. Curr. Opin. Neurol. 16 (2003) 393-401
49. Tobert J.A. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug Discov. 2 (2003) 517-526
50. Vasilevko V., and Cribbs D.H. Novel approaches for immunotherapeutic intervention in Alzheimer's disease. Neurochem. Int. 49 (2006) 113-126
51. Vaughan C.J., and Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 30 (1999) 1969-1973
52. Vaughan C.J., Murphy M.B., and Buckley B.M. Statins do more than just lower cholesterol. Lancet 348 (1996) 1079-1082
53. Wassmann S., and Nickenig G. Interrelationship of free oxygen radicals and endothelial dysfunction-modulation by statins. Endothelium 10 (2003) 23-33
54. Wolozin B. Cholesterol and Alzheimer's disease. Biochem. Soc. Trans. 30 (2002) 525-529
55. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., and Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57 (2000) 1439-1443
56. Wood W.G., Schroeder F., Avdulov N.A., Chochina S.V., and Igbavboa U. Recent advances in brain cholesterol dynamics: transport, domains, and Alzheimer's disease. Lipids 34 (1999) 225-234
57. Wood W.G., Schroeder F., Igbavboa U., Avdulov N.A., and Chochina S.V. Brain membrane cholesterol domains, aging and amyloid beta-peptides. Neurobiol. Aging 23 (2002) 685-694
58. Xiu J., Nordberg A., Shan K.R., Yu W.F., Olsson J.M., Nordman T., Mousavi M., and Guan Z.Z. Lovastatin stimulates up-regulation of alpha7 nicotinic receptors in cultured neurons without cholesterol dependency, a mechanism involving production of the alpha-form of secreted amyloid precursor protein. J. Neurosci. Res. 82 (2005) 531-541
59. Xiu J., Nordberg A., Qi X.L., and Guan Z.Z. Influence of cholesterol and lovastatin on α-form of secreted amyloid precursor protein and expression of α7 nicotinic receptor on astrocytes. Neurochem. Int. 49 (2006) 459-465